论文部分内容阅读
1999年 2月至 11月我科使用新近上市的由中日合资杰希药业公司生产的杰希尿激酶和南京制药厂生产的南京尿激酶治疗急性心肌梗塞 (AMI) 6 5例 ,旨在观察杰希尿激酶疗效及安全性。1 对象和方法 对象 :对符合 AMI溶栓治疗且有条件行溶栓后 90分冠状动脉造影的 6 5例AMI患者 ,
From February to November 1999, 65 subjects of newly diagnosed acute myocardial infarction (AMI) treated with Jiexiu urokinase from Sino-Japanese joint venture Jiexi Pharmaceutical Company and Nanjing urokinase from Nanjing Pharmaceutical Factory were used in our department. To observe Jie Xi urokinase efficacy and safety. 1 Subjects and Methods Subjects: Sixty-five patients with acute myocardial infarction (AMI) who underwent AMI thrombolysis and were eligible for coronary angiography at 90 minutes after thrombolysis,